tradmap

IDXX Financials Idexx Laboratories

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 9.7% per year over the past 5 years.
  • Net income has grown faster than revenue (12.7% vs 9.7% per year).
  • Operating margin has expanded, at 31.6% in the latest year.
  • Free cash flow has grown 14.3% per year over the past 5 years.

Financial health

  • Total debt ($450M) exceeds cash ($180M); net debt is $270M.
  • Total debt has grown slower than revenue (-13.1% vs 9.7% per year).
  • Operating income covered interest expense 35× in the latest year.
  • Total debt is 0.3× EBITDA.
Revenue & net income
$0 $2B $4B 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
0% 31% 62% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Free cash flow (CFO − capex)
$0 $529M $1B 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $455M $909M 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$1B $8M $1B $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 $4.3B $1.1B 61.8% 31.6% $1.1B $450M $180M
2024 $3.9B $888M 61.0% 29.0% $808M $618M $288M
2023 $3.7B $845M 59.8% 30.0% $773M $698M $454M
2022 $3.4B $679M 59.5% 26.7% $394M $770M $113M
2021 $3.2B $745M 58.8% 29.0% $636M $851M $144M
2020 $2.7B $582M 58.0% 25.7% $541M $909M $384M
2019 $2.4B $428M 56.7% 23.0% $304M $699M $90M
2018 $2.2B $377M 56.1% 22.2% $284M $602M $124M
2017 $2.0B $263M 55.7% 21.0% $299M $607M $188M
2016 $1.8B $222M 54.9% 19.7% — $594M $155M
2015 — $192M — — — $597M $129M
2014 — $182M — — $175M $350M $323M
2013 — $188M — — $168M $151M $279M
2012 — $178M — — $165M $3M $224M
2011 — $162M — — $168M $3M $184M

Valuation over time

How the market has priced IDXX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 33.5 66.9 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/E
Price / sales (P/S)
0.0 7.6 15.2 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/S

Frequently asked questions

Is IDXX growing its revenue and profit?

Over the past 5 years, Idexx Laboratories's revenue has grown 9.7% per year, and net income grown 12.7% per year. These are computed facts, not advice.

How much debt does IDXX have?

As of FY2025, Idexx Laboratories reported $450M of total debt against $180M of cash; operating income covered interest expense 35×.

What is IDXX's profit margin?

In FY2025, gross margin was 61.8%, operating margin 31.6%, and net margin 24.6%.

What is IDXX's P/E ratio?

As of Jun '26, Idexx Laboratories traded at a price-to-earnings ratio of about 41.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.